Physician profile
Steve Yu
NPI 1528251410
$963,504.20
in general payments reported to CMS, 2019-2025
12 companies · $51K in 2025
The $51K reported for 2025 was more than what 99% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $1,513 · 2021: $7,268 · 2022: $322K · 2023: $431K · 2024: $150K · 2025: $51K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $571K · Travel and Lodging: $52K · Food and Beverage: $9,004.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $570,900.00 |
| Travel and Lodging | $52,435.76 |
| Food and Beverage | $9,003.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acessa Health INC. | $919,241.61 | 2020-2025 | Acessa Provu System |
| Hologic Sales and Service, LLC | $41,315.39 | 2021-2025 | Acessa Provu System, None, Coolseal Generator |
| Cytyc Surgical Products, LLC | $2,327.06 | 2025 | Acessa Provu System |
| Meditrina | $155.36 | 2021-2024 | |
| Mimedx Group, INC. | $143.01 | 2025 | |
| Intuitive Surgical, INC. | $118.53 | 2021-2022 | |
| Biotissue Holdings INC. | $72.58 | 2025 | |
| Sumitomo Pharma America, INC. | $41.82 | 2025 | Myfembree |
| Legend Biotech USA INC. | $30.78 | 2025 | Carvykti |
| Aimmune Therapeutics, INC. | $22.53 | 2025 | Vowst |
| Innovation Technologies INC | $22.04 | 2021 | |
| Merck Sharp & Dohme LLC | $13.49 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steve Yu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.